Valsartan

On July 13, 2018, the FDA announced a Class I recall of certain batches of Valsartan, a drug used to treat hypertension and heart failure. The Valsartan Litigation Group strives to synthesize a wide array of information, serving as a forum for discussion on litigation strategy, case criteria, and expert testimony. Members will be kept up to date on the science and applicable law on the Valsartan litigation, receiving sample pleadings and group materials that incorporate recommendations from experts.

• Meetings: The group meets at AAJ Annual and Winter conventions.

• Membership: The group is limited to AAJ Regular, Life, Sustaining, and President’s Club members only.

• Annual Dues: The Litigation Group is complementary to members of the AAJ Pharmaceutical and Medical Device Section who can agree to the terms and conditions of membership in the Litigation Group's Affidavit. If you are not yet a member, you can join the Pharmaceutical and Medical Device Section here.

Cochairs

Marlene Goldenberg | Nigh Goldenberg Raso & Vaughn, Washington, DC

George Williamson | Farr Farr Emerich Hackett & Carr, PA, Punta Gorda, FL

Conlee Whiteley | Kanner & Whiteley LLC, New Orleans, LA

Daniel Nigh | Nigh Goldenberg Raso & Vaughn, Gulf Breeze, FL